Anupam Rasayan India Ltd shared the transcript of its Q2 and H1 FY25 earnings call, noting a consolidated revenue of Rs. 294 crores for Q2 which is down 25% from the previous year, with EBITDA margins at around 28%. The company anticipates growth from its pharma and polymer segments, expecting them to contribute over 15% to total revenue for the full year.